Trastuzumab deruxtecan (solution)
Based on 13 publication(s) in Google Scholar
Trastuzumab deruxtecan (T-DXd; DS-8201a) (solution) is an anti-human epidermal growth factor receptor 2 (HER2) antibody-drug conjugate (ADC). Trastuzumab deruxtecan is composed of a humanized anti-HER2 antibody, an enzymatically cleavable peptide-linker, a topoisomerase I inhibitor (a toxin component of Dxd), and the drug-linker conjugate for ADC is Deruxtecan (HY-13631E). Trastuzumab deruxtecan can be used for the research of HER2-positive breast cancer and gastric cancer.
연구목적의 판매만을 진행합니다. 환자를 대상으로 한 판매는 하지 않습니다.
- Purity : 98.20%
- CAS No.: 1826843-81-5
- 분자량:153000 (average)
-
보관:Shipping with dry ice
-80°C, protect from light
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Protocol
- 순도&문서
- References
-
Help & FAQs
-
HY-P9921A
Trastuzumab emtansine (solution)Antibody-Drug Conjugate -
HY-P99016B
Enfortumab vedotin-ejfv (solution)Nectin-4 ADC -
HY-132254
Sacituzumab govitecanTrop-2 ADC -
HY-P9921
Trastuzumab emtansineAntibody-drug Conjugate -
HY-138298A
Trastuzumab deruxtecanHER2 ADC -
HY-P99107A
Brentuximab vedotin (solution)ADC -
HY-132254A
Sacituzumab govitecan (solution)Trop-2 ADC -
HY-P9907
TrastuzumabHER2 Blocking Antibody -
HY-141598
Datopotamab deruxtecan (solution)TROP2-Targeted ADC -
HY-P9985
Disitamab vedotinHER2-Directed ADC -
HY-P99016A
Enfortumab vedotin-ejfvNectin-4 ADC -
HY-132258A
Mirvetuximab soravtansine (solution)ADC
Publications Citing Use of MedChemExpress (MCE) Trastuzumab deruxtecan (solution)
More- Cancer Discov. 2026 Apr 2. [Abstract]
- Cell Death Dis. 2026 Jul 6.
- Clin Cancer Res. 2026 Jul 21.
- Mol Cancer Ther. 2026 Mar 26. [Abstract]
- Sci Rep. 2026 May 7. [Abstract]
- Cancers (Basel). 2026 Mar 19;18(6):997. [Abstract]
- Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
- J Anal Sci Technol. 2026 Sep 28;17(1):50.
- Seoul National University. 2026.
- bioRxiv. 2026 Jun 19.
- bioRxiv. 2026 May 27.
- Saint Joseph University. 2026.
- Biomed Pharmacother. 2023 Jul:163:114751. [Abstract]
Customer Validation & Images
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
-
Cell Proliferation/Viability Assay
All EGFR Isoforms
More
Biological Activity
제품 설명
In Vitro
Trastuzumab deruxtecan (1 pM-10 nM; 5 days) (solution) inhibits the growth of HER2-positive KPL-4 cells, with an IC50 of 109.7 pM[2].
Trastuzumab deruxtecan (10 nM; 5 days) (solution) shows bystander killing effects in HER2-negative MDA-MB-468 cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KPL-4 and MDA-MB-468 cells
-
Concentration:1, 10, 100, 1000, 10000 pM
-
Incubation Time:5 days
-
Result:Killed HER2-positive KPL-4 cells only.
In Vivo
Trastuzumab deruxtecan (10 mg/kg; i.v. on days 0 and 7) (solution) inhibits the tumor growth in in EMT6-hHER2 syngeneic mouse model[3].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Female BALB/c nude mice injected with NCI-N87 and MDA-MB-468-Luc cells[2]
-
Dosage:3 mg/kg
-
Administration:A single i.v.
-
Result:Almost all of the HER2-positive and HER-negative cells disappeared and there were little or no cancer cells remaining in the tumors.
Chemical Information
-
CAS No. 1826843-81-5
-
Appearance Liquid
-
분자량 153000 (average)
-
Color Colorless to light yellow
-
SMILES
[Trastuzumab deruxtecan (solution)]
-
Synonyms
T-DXd (solution); DS-8201 (solution); DS-8201a (solution)
-
선적
Shipping with dry ice.
-
보관
-80°C, protect from light
Publications (13)
-
Journal Impact Factor
-
Most Recent
-
Cancer Discov
HER2 heterogeneous breast cancer models reveal novel therapeutic targets and subclonal dynamics during evolution to resistance to HER2-targeted therapies. [Abstract]2026 Apr 2. PMID: 41925564 -
-
-
Mol Cancer Ther
Antibody-drug-conjugates prepared with Peptide Asparaginyl Ligases achieve strong in vitro and in vivo anti-tumor activity. [Abstract]2026 Mar 26. PMID: 41889275 -
Sci Rep
Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates. [Abstract]2026 May 7. PMID: 42098228 -
Cancers (Basel)
Characterization of HER2-Positive Murine Breast Cancer Models for Investigating HER2-Targeted Therapy and Immunotherapy. [Abstract]2026 Mar 19;18(6):997. PMID: 41899598 -
Biochem Biophys Res Commun
3D layered co-culture model enhances Trastuzumab Deruxtecan sensitivity and reveals the combined effect with G007-LK in HER2-positive non-small cell lung cancer. [Abstract]2024 Sep 17:725:150255. PMID: 38897043
Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
Trastuzumab deruxtecan (1 μg/mL; 120 h). H2170 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.
Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
Trastuzumab deruxtecan (0-10 μg/mL; 72 h). JFCR-007 Luc-ZsG-positive cells were treated with T-DXd for 72 h in each co-culture conditions. Cell viability was measured by ONE-Glo Luciferase Assay.
Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
Trastuzumab deruxtecan (0-10 μg/mL; 120 h). The indicated cells were treated with serially diluted T-DXd for 120 h in a 2D culture condition.
Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
JFCR-007 was treated with or without T-DXd (10 μg/mL) for 120 h in spheroid condition.
Trastuzumab deruxtecan (solution) purchased from MedChemExpress. Usage Cited in: Biochem Biophys Res Commun. 2024 Sep 17:725:150255. [Abstract]
Trastuzumab deruxtecan (1 μg/mL; 120 h). JFCR-007 was treated with the indicated drugs and concentrations. Cell viability was measured by CellTiter-Glo assay or ONE-Glo Luciferase Assay.
-
-
-
-
-
-
Biomed Pharmacother
Patient-derived organoid culture of gastric cancer for disease modeling and drug sensitivity testing. [Abstract]2023 Jul:163:114751. PMID: 37105073
순도&문서
-
Data Sheet (275 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
Handling Instructions (2659 KB)
References
[1]. Kumagai K, et al. Interstitial pneumonitis related to trastuzumab deruxtecan, a human epidermal growth factor receptor 2-targeting Ab-drug conjugate, in monkeys. Cancer Sci. 2020 Dec;111(12):4636-4645. [Content Brief]
[2]. Kotani D, et, al. Trastuzumab deruxtecan for the treatment of patients with HER2-positive gastric cancer. Ther Adv Med Oncol. 2021 Jan 7;13:1758835920986518. [Content Brief]
[3]. Ogitani Y, et, al. Bystander killing effect of DS-8201a, a novel anti-human epidermal growth factor receptor 2 antibody-drug conjugate, in tumors with human epidermal growth factor receptor 2 heterogeneity. Cancer Sci. 2016 Jul;107(7):1039-46. [Content Brief]
[4]. Iwata TN, et, al. [Fam-] trastuzumab deruxtecan (DS-8201a)-induced antitumor immunity is facilitated by the anti-CTLA-4 antibody in a mouse model. PLoS One. 2019 Oct 1;14(10):e0222280. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Trastuzumab deruxtecan (solution) Related Classifications
HY-138298 Related Classifications
Powered by Bioz
Keywords